Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.

In an interview last month with former Fox News journalist Megyn Kelly, Makary unveiled plans for a new regulatory pathway for rare disease drugs, allowing for their conditional approval based on a ...

Promising results show that abelacimab could revolutionize anticoagulation therapy by ... fewer clots without notable bleeding, making this pathway an attractive focus for safer anticoagulants.

ABSTRACT: Background: Preeclampsia is reported to complicate 2% - 8% of pregnancies globally and is an important cause of maternal and perinatal morbidity and mortality. The aetiology and pathogenesis ...

How the identification of these cardiomyopathy gene variants should influence the use of anticoagulation therapy for a patient with early-onset AF is still undefined. In this review, we sought to ...

recent thrombosis in the Fontan pathway within 6 months). Intermediate risk (reasonable to use anticoagulation): Atrial arrhythmias under control (≥6 months), history of remote stroke and an open ...

Participants were randomized in a 1:1 ratio to either (1) usual care (UC) or (2) our SDM Pathway stratified by study site, prior anticoagulation history, and CHA 2 DS 2 ‐VASc score. A random ...

Based in these findings, the team introduced the Safe Anticoagulation for Atrial Fibrillation (SAFE) emergency department (ED) pathway, for the initiation of treatment in patients with AF. The SAFE ...

Patients with a recent history of anticoagulation therapy ... Considering the complex interplay between prothrombotic and anti-haemostatic pathways, their influence on outcome in terms of thrombosis ...